A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes.
Wilkinson, SR; Taylor, MC; Horn, D; Kelly, JM; Cheeseman, I; (2008) A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proceedings of the National Academy of Sciences of the United States of America, 105 (13). pp. 5022-7. ISSN 0027-8424 DOI: 10.1073/pnas.0711014105
Nifurtimox and benznidazole are the front-line drugs used to treat Chagas disease, the most important parasitic infection in the Americas. These agents function as prodrugs and must be activated within the parasite to have trypanocidal effects. Despite >40 years of research, the mechanism(s) of action and resistance have remained elusive. Here, we report that in trypanosomes, both drugs are activated by a NADH-dependent, mitochondrially localized, bacterial-like, type I nitroreductase (NTR), and that down-regulation of this explains how resistance may emerge. Loss of a single copy of this gene in Trypanosoma cruzi, either through in vitro drug selection or by targeted gene deletion, is sufficient to cause significant cross-resistance to a wide range of nitroheterocyclic drugs. In Trypanosoma brucei, loss of a single NTR allele confers similar cross-resistance without affecting growth rate or the ability to establish an infection. This potential for drug resistance by a simple mechanism has important implications, because nifurtimox is currently undergoing phase III clinical trials against African trypanosomiasis.
|Faculty and Department:||Faculty of Infectious and Tropical Diseases > Dept of Pathogen Molecular Biology|
|Research Centre:||Antimicrobial Resistance Centre (AMR)
|Web of Science ID:||254723700014|
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Actions (login required)